source
- Cerevance's solengepras cuts OFF time in phase 3 Parkinson's trialCerevance reported that its oral non‑dopaminergic therapy, solengepras, produced meaningful improvements in both motor and non‑motor symptoms in a phase 3 Parkinson's disease study, rescuing the ca…
- Dutch court orders Merck to halt subcutaneous Keytruda sales in eight European countriesA Dutch court has issued an injunction that requires Merck to stop manufacturing and selling the injectable, subcutaneous formulation of its cancer immunotherapy Keytruda in eight European countrie…